DKFZp779M0652
DKFZp779M0652: A Comprehensive Guide to the Promising Prostate Cancer Biomarker
Introduction:
DKFZp779M0652 is a recently discovered protein that has gained significant attention in the field of prostate cancer research. This novel biomarker has shown promising potential in aiding diagnosis, prognosis, and treatment decisions for this common and potentially life-threatening condition.
Description:
DKFZp779M0652 is a member of the urokinase plasminogen activator receptor (uPAR) family of proteins. It is primarily expressed in the prostate gland and plays a crucial role in cell signaling, adhesion, and migration. Research suggests that elevated levels of DKFZp779M0652 are associated with prostate cancer progression and aggressiveness.
Associated Diseases:
The primary association of DKFZp779M0652 is with prostate cancer. Studies have found that increased expression of this biomarker is linked to:
- Prostate cancer development: High levels of DKFZp779M0652 have been observed in prostate tumor cells, indicating its involvement in tumorigenesis.
- Tumor progression: Increased DKFZp779M0652 expression has been correlated with greater tumor size, higher Gleason scores, and more aggressive disease behavior.
- Metastasis: DKFZp779M0652 has been implicated in the metastatic process, as higher levels are associated with increased risk of cancer spreading to other parts of the body.
Did you Know ?
A large-scale study published in the journal "Clinical Cancer Research" found that patients with high levels of DKFZp779M0652 had a 3-fold increased risk of biochemical recurrence (a sign of cancer recurrence) after radical prostatectomy, a common surgical treatment for prostate cancer.
